Curebase
Provider of decentralized clinical research software solutions and services to patients and medical providers.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | $40.0m | Series B | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2023 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 149 % | 150 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Curebase operates in the clinical trials industry, providing innovative software solutions designed to enhance patient engagement and data accuracy. The company serves pharmaceutical companies, medical device manufacturers, and contract research organizations (CROs) by offering a suite of tools including ePRO (electronic Patient-Reported Outcomes), eCOA (electronic Clinical Outcome Assessments), eConsent, and EDC (Electronic Data Capture). These tools are highly configurable, allowing for rapid study launches and optimized participant experiences. Curebase's business model revolves around licensing its software to clients, who use it to streamline their clinical trials, improve data quality, and ensure regulatory compliance. Revenue is generated through subscription fees and service contracts. The company operates in a competitive market but differentiates itself with its focus on user-friendly design and robust data collection capabilities.
Keywords: clinical trials, ePRO, eCOA, eConsent, EDC, patient engagement, data accuracy, pharmaceutical, medical devices, CROs.